Have your say!
Would you like to share your views to help improve programs and services for patients, or help researchers gain a better understanding of the challenges of living with kidney disease?
Our Kidney Community Contact List is a national and confidential record of people willing to be contacted for their feedback and action on topics of concern to people living with kidney disease. Join our contact list and we will contact you as opportunities arise.
What are the Research Priorities of People with Kidney Disease?
Because people with kidney disease and those who care for them live with their kidney disease and its treatment every day, it is important to understand what their research priorities are.
Researchers at the University of Calgary are inviting people with kidney disease not yet on dialysis to share ideas about what is needed to improve the treatment and quality of life of people with kidney disease. This includes people with an estimated kidney function of <45%, who are not receiving dialysis and have not received a kidney transplant.
The survey takes approximately 5 to 10 minutes to complete and is available in English or French (language can be selected in the top right corner of the screen). You will be asked to identify questions (about diagnosis, prognosis, treatment, and anything else) that you think should be studied through research. All answers will be completely confidential and anonymous. The survey will be available until January 31, 2015.
This University of Calgary research study is funded by the Interdisciplinary Chronic Disease Collaboration (www.ICDC.ca) and supported by The Kidney Foundation of Canada.
Seeking Patients and Nurses Feedback on AK96 and AK95 Home Dialysis Machines
CRC Research is seeking patients and nurses using AK96 and AK95 home dialysis machines to participate in a 2.5 hour interview in Mississauga, Ontario between Nov. 24 to Dec. 3, 2014. Participants will be remunerated and those travelling to the interview within a two-hour radius will have their mileage reimbursed.
To confirm your eligibility please fill out this online questionnaire: https://www.surveymonkey.com/s/8NVLGKZ
Eligible participants should contact Aziza Oubella at 1-866-272-4959 or by email at firstname.lastname@example.org.
Walking and Health in Adults with a Kidney Transplant
Researchers at Athabasca University want to learn about the health outcomes associated with walking behaviour in adult kidney transplant recipients.
Study participants must be over the age of 18, have a functioning kidney transplant, be able to walk without assistance (cane, walker, wheelchair), and be able to read and understand English. Participants will be asked to wear a pedometer for three days and record their number of steps, then complete and return a survey (postage paid).
Download this document for more information or contact Ms. Josée Raymond at 249-878-0088 or via email at email@example.com.
Clinical Trial Studying New Non-surgical Vascular Access Method for Hemodialysis
The Novel Endovascular Access Trial (NEAT) is evaluating the safety and efficacy of the FLEX endoAVF System from TVA Medical, a device that creates an arteriovenous fistula (AVF) in a percutaneous procedure, without general anesthesia or surgery. In the procedure, two thin, flexible magnetic catheters are inserted in an artery and vein in the arm. A small burst of radiofrequency energy is used to connect the artery and vein to create the fistula, and the catheters are removed. The procedure is designed to enable patients to use their AVF for hemodialysis within one to two months.
Five hospitals in Canada are enrolling up to 70 patients in total who will be followed for 12 months in the NEAT clinical trial. The centers include St. Paul’s Hospital in Vancouver; Montreal University Health Centre (CHUM) in Montreal; Toronto General Hospital in Toronto; Lakeridge Health in Oshawa, Ontario; and Victoria Hospital in London, Ontario. NEAT study participants must be willing to travel to one of the trial sites on a monthly basis for one year for hemodialysis and follow-up appointments.
Patients with end-stage (stage IV or V) renal disease interested to enroll in this trial should read this Patient FAQ and talk to their nephrologist before contacting the participating hospital in their region.